Haleon PLC receives Investment Bank Analyst Rating Update
By Scott Kanowsky Investing.com -- Shares in HALEON PLC (LON:HLN) edged higher after the consumer healthcare firm rejected requests for indemnification from GSK (LON:GSK) and ...
Leading shares are heading higher after the Bank Holiday break, helped by a late recovery on Wall Street. The FTSE 100 is up 65.37 points or 09% in early trading at...
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.